FDA finalizes guidances to accelerate the development of reliable, beneficial next generation sequencing-based tests The U.S. Food and Drug Administration on April 12th finalized two guidances to drive the efficient development of a novel technology that scans a person’s DNA to diagnose genetic diseases, which are usually hereditary, and guide medical treatments. The guidances provide […]
About Ben Harmssen
This author has yet to write their bio.Meanwhile lets just say that we are proud Ben Harmssen contributed a whooping 10 entries.
Entries by Ben Harmssen
Foundation Medicine Announces Commercial Availability of FoundationOne CDx, the First FDA-Approved Comprehensive Genomic Profiling Assay for All Solid Tumors Incorporating Multiple Companion Diagnostics. Foundation Medicine, Inc. announced on March 30th, 2018 that FoundationOne CDx(TM), the first U.S. Food and Drug Administration (FDA) approved comprehensive genomic profiling (CGP) assay for all solid tumors incorporating multiple companion […]
This is an in depth review of the American Society of Clinical Oncology’s (ASCO) panel on their State of Cancer in America annual report released January 31st, 2018. MyOncoPath is dedicated to providing cancer patients and oncology providers with genetic counseling for somatic and diagnostic genetic testing to expand access to precision medicine.
The U.S. Food and Drug Administration today expanded the approved use of Lynparza (olaparib tablets) to include the treatment of patients with certain types of breast cancer that have spread (metastasized) and whose tumors have a specific inherited (germline) genetic mutation, making it the first drug in its class (PARP inhibitor) approved to treat breast […]
In May 2017 the FDA granted accelerated approval to an immunotherapy cancer treatment for patients whose cancers have a specific genetic feature (biomarker). This approval marked the first time the FDA approved a cancer treatment based on a common biomarker rather than the location in the body where the tumor originated. Keytruda is a cancer […]
FDA Announces Approval of FoundationOne CDx, Foundation Medicine’s Cancer Gene Diagnostic Test for Solid Tumors FDA approves test to detect mutations in 324 genes, two genomic signatures. Second to be approved with proposed coverage under FDA/CMS Parallel Review Program. Agencies’ parallel review process makes test for efficient identification of multiple targeted therapy options available to […]
The Use of Telecommunications to Improve Access to Cancer Treatments For many telemedicine is new and possibly unknown. Although telemedicine has been around since the 1950’s, today telemedicine is growing exponentially with an overall net benefit. Here at MyOncoPath telemedicine is our business model: we were founded with the goal of providing patients and health […]
An Immunotherapy targets a cancer patient’s immune system with the goal of activating the immune system to attack cancer cells, where as a chemotherapy, generally kills cells that are reproducing (hence some of the side effects like hair loss are common). Immunotherapy is a type of cancer treatment that boost’s the body’s immune defenses to fight […]
Liquid biopsy is a hot topic in oncology today, as it opens up possibility, access, and understanding into the world and makeup of cancer cells. For MyOncoPath, liquid blood biopsies are another genetic test to help understand individual cancers and move into precision medicine and away from the one-size fits all approach to treatment plans. […]
Molecular profiling, also known as tumor profiling or cancer profiling, is genetic testing of cancer DNA to identify the specific genetic makeup of the cancer. All cells are made up of genes, which contain genetic codes. Every cancer cell has its own genetic code or profile. The molecular profile of the cancer reveals characteristics about […]